Sharemaestro Newsreel

Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. significantly increased its stake in Gilead Sciences, Inc. by 346.5% in the second quarter, now owning 2,287,888 shares worth $289,052,000. Other institutional investors also adjusted their positions in the biopharmaceutical company. Gilead Sciences reported strong Q2 revenue of $7.8 billion, …

Merck lifts 2026 outlook as profits surge &Bio-Techne deal strengthens growth push

Merck has raised its full-year guidance for 2026 after reporting stronger-than-expected second-quarter results, driven by growth in life science, rare diseases, and semiconductor solutions. The company's proposed acquisition of Bio-Techne Corporation is expected to further bolster its leadership in high-growth life science markets. Merck …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Pharmaceuticals, Inc. announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs, an obesity treatment candidate designed to preserve lean body mass. The study demonstrated rapid oral absorption and dose-dependent systemic exposure, de-risking dose selection and supporting advancement toward …

Why Pfizer (PFE) Is Up 5.2% After Raising 2026 Guidance Despite a Q2 Net Loss

Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities

Gilead Sciences has filed an automatic shelf registration statement on Form S-3, enabling it to offer a wide range of securities, including debt, common stock, preferred stock, and warrants, from time to time. This broad filing allows the company flexibility in future fundraising, with …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Pomerantz LLP is investigating potential claims on behalf of investors of AstraZeneca PLC (NYSE: AZN) following a significant drop in its stock price. This investigation comes after AstraZeneca disclosed that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet …

Biogen completes acquisition of RayThera, advancing immunology pipeline with Phase 1 lead program

Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This acquisition strengthens Biogen's immunology portfolio by adding multiple assets, with RayThera's lead program having entered Phase 1 clinical development in July 2026. The deal underscores Biogen's …

Novo Nordisk Awards U.S. Media Account to Omnicom 08/07/2026

Pharmaceutical giant Novo Nordisk has selected Omnicom as its U.S. media agency of record following a review. The company spends approximately $600 million annually on media and previously worked with WPP's Wavemaker. This new partnership aims to scale consumer-focused strategies and connect with patients, …

ABBV6474383 Bond Price and Chart — FINRA:ABBV6474383

This article provides details about the ABBV6474383 bond issued by AbbVie Inc. It lists key terms such as the coupon rate (5.45%), maturity date (September 15, 2038), and outstanding amount. The article also includes company information for AbbVie, Inc., describing it as a research-based …

Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

A U.S. federal judge has dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk filed by compounding pharmacy Strive Specialties. Strive had accused the pharmaceutical giants of illegally blocking access to customized versions of their GLP-1 weight-loss drugs through exclusive deals with telehealth …

Pfizer Inc Earnings Call Signals Cautious Optimism

Pfizer Inc.'s Q2 earnings call revealed cautious optimism, with core revenues and adjusted EPS surpassing expectations, leading to raised full-year revenue guidance. The company demonstrated strong performance in oncology and neuroscience, alongside significant R&D activity, despite setbacks from a clinical trial miss, weaker COVID …

Press Release: Biogen Completes Acquisition of RayThera Inc.

Biogen has successfully completed its acquisition of RayThera Inc., a biotechnology company specializing in novel oncology treatments. This strategic acquisition aims to expand Biogen's pipeline in oncology and leverage RayThera's innovative research. The integration of RayThera's assets is expected to strengthen Biogen's position in …

Biogen completes acquisition of immunology firm RayThera By Investing.com

Biogen Inc. has completed its acquisition of RayThera Inc., an immunology-focused biotechnology company. This acquisition expands Biogen's immunology portfolio with multiple small-molecule assets targeting immune-mediated conditions, including a lead program that entered Phase 1 development in July 2026. The financial terms of the transaction …

Biogen's RayThera Deal Adds a Phase 1 Immunology Program

Biogen (Nasdaq: BIIB) has announced the completion of its acquisition of RayThera Inc., a private biotechnology company specializing in small-molecule immunology therapies. This acquisition enhances Biogen's immunology portfolio by introducing multiple assets, including a lead program that entered Phase 1 development in July 2026. …

NAACP, Sanofi Announce Interactive Health Equity Map, Making Nearly 23,000 Community Voices "Impossible to Ignore"

The NAACP and Sanofi have launched an interactive health equity map called "Black Communities' Health: In Plain Sight." This tool uses data from nearly 23,000 residents across 47 states, D.C., and Puerto Rico to highlight health disparities at the ZIP-code level, focusing on access …

Sanofi Pauses Phase 2 Trial of Monoclonal Antibody SAR445399 in Chronic Lung Disease

Sanofi has suspended a phase 2 trial of its monoclonal antibody SAR445399 for non-cystic fibrosis bronchiectasis. The decision stems from a company-wide portfolio review under new CEO Belén Garijo, not safety concerns. This pause follows other recent pipeline adjustments as Sanofi reassesses its late-stage …

OGN (NYSE: OGN) details 14,761-share Rule 144 common stock sale plan

Organon & Co. (OGN) has filed a Rule 144 notice for the proposed sale of 14,761 shares of common stock through Morgan Stanley Smith Barney LLC, valued at $200,306.77. The filing also details future restricted stock vesting events, including 2,384 shares on November 7, …

Merck Animal Health awards $50,000 in vet scholarships

Merck Animal Health has awarded $50,000 in scholarships to five veterinary students specializing in poultry health, in partnership with the American Association of Avian Pathologists (AAAP) Foundation. This marks the 11th year of the program, which has now distributed over $280,000. The recipients were …

Novo Nordisk: what the Danish pharma giant does and makes

Novo Nordisk is a Danish pharmaceutical giant founded in 1923, primarily known for its diabetes and obesity treatments, including the blockbuster drugs Ozempic and Wegovy. The company's core business revolves around insulin and GLP-1 receptor agonists like semaglutide, with a significant portion of its …

Novartis Ag (0K9E) Q2 2026 Earnings Report - Results, Call & Slides

Novartis Ag reported strong Q2 2026 earnings, beating analyst expectations with an EPS of $2.41 and revenue of $14.42 billion. The company reaffirmed its full-year guidance, driven by robust performance from priority brands like KISQALI, LEQVIO, and Scemblix, and significant progress in its pipeline …

This Will be Eli Lilly’s Price in 2027 And Morgan Stanley Agrees

Eli Lilly (LLY) recently reported a strong quarter with significant revenue and EPS growth, leading management to raise full-year guidance. Despite this, the stock has underperformed due to acquisition charges and pricing pressures. While analysts are mostly bullish, the article suggests their price targets …

Johnson & Johnson: what the healthcare giant makes and does

Johnson & Johnson is a global healthcare giant, founded in 1886, that now focuses primarily on pharmaceuticals and medical devices after spinning off its consumer health division, Kenvue, in 2023. The company's operations span Innovative Medicine (pharmaceuticals) and MedTech segments, with a significant emphasis …

Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com

This article announces that Mira Pharmaceuticals Inc. filed a Form 8K on August 6. The content is very brief, mainly serving as a notification about the SEC filing. The company's stock symbol is MIRA, and it showed a 9.11% increase.

What the AstraZeneca-BMS rumors reveal about pharma megamergers

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb, which would have created a $400 billion pharmaceutical giant, were quickly disputed. While AstraZeneca's strong pipeline makes a merger less appealing for them, Bristol Myers Squibb could benefit due to impending patent expirations …

The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS

The Manufacturers Life Insurance Company reduced its stake in Novartis AG by 39.4% in the first quarter, selling 24,216 shares and retaining 37,202 shares valued at $5.68 million. Despite this, other major institutions like Morgan Stanley and Fisher Asset Management increased their holdings, with …

Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD)

FMR LLC discloses 12.4% Biogen Inc (BIIB) stake totaling 18.29M shares

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 18,294,523.51 shares of Biogen Inc. (BIIB) common stock, which represents a 12.4% stake in the company. FMR LLC holds sole voting power over 16,623,432.57 shares and sole dispositive power over all 18.29 …

AbbVie Inc. (ABBV) Stock forecasts

Argus Research has raised its target price for AbbVie Inc. (ABBV) to $270, noting the company's status as a research-based biopharmaceutical firm spun off from Abbott Laboratories. AbbVie is a component of the S&P 500, with its shares currently trading at $244.93. The report …

Amgen separates from weak drugmaker group, but 31% fair-value gap raises the bar

AMGN added 2.4% in the week to 31 July and sits only 3.2% below its 52-week high, with the Trend Signal active but volume confirmation still modest.

Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs

Eli Lilly exceeded Wall Street's second-quarter revenue estimates due to the strong performance of its injectable GLP-1 drugs, Mounjaro and Zepbound, leading to a raised full-year revenue forecast. Injectables continue to dominate new patient starts for obesity treatment, even as oral options become available, …

Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses

Novavax (NVAX) exceeded second-quarter earnings and revenue expectations and raised its full-year 2026 revenue guidance. This positive outlook is supported by continued progress in its collaboration with Sanofi, including advanced discussions for a Phase 3 trial of a combined COVID-19 and influenza vaccine, which …

Biogen Inc. completed the acquisition of RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others.

Biogen Inc. has completed the acquisition of RayThera, Inc. for a total consideration of $1 billion. The deal includes an upfront cash payment of $225 million and an additional $775 million contingent on future clinical and regulatory milestones. This acquisition, which excludes certain preclinical …

MIRA's obesity candidate shows rapid absorption in 7-day dog study

MIRA Pharmaceuticals reported positive toxicokinetic results from a 7-day repeated-dose study of its obesity candidate, SKNY-1, in Beagle dogs. The study showed rapid absorption, dose-dependent systemic exposure, and systemic accumulation, which de-risks dose selection for planned GLP toxicology studies. These findings support the advancement …

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

Novo Nordisk has won a lawsuit in the Netherlands against Ceban Ziekenhuisfarmacie, a compounding pharmacy that was distributing a nasal spray formulation of semaglutide called Semanova. The court ruled that Ceban infringed on Novo Nordisk's supplementary protection certificate (SPC) for semaglutide, which protects Ozempic, …

Merck bid to expand label for RSV shot under FDA review (MRK)

Merck announced that the FDA has accepted its marketing application to expand the U.S. label for Enflonsia, its RSV antibody therapy. The treatment aims to protect infants from the respiratory syncytial virus. The prophylactic treatment had been previously approved by the FDA.